The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation
Open accessAbstract
In the race for a safe and effective vaccine against coronavirus disease (COVID)-19, pharmaceutical formulation science plays a critical role throughout the development, manufacturing, distribution, and vaccination phases. The proper choice of the type of vaccine, carrier or vector, adjuvant, excipients, dosage form, and route of administration can directly impact not only the immune responses induced and the resultant efficacy against COVID-19, but also the logistics of manufacturing, storing and distributing the vaccine, and mass vaccination. In this review, we described the COVID-19 vaccines that are currently tested in clinical trials and provided in-depth insight into the various types of vaccines, their compositions, advantages, and potential limitations. We also addressed how challenges in vaccine distribution and administration may be alleviated by applying vaccine-stabilization strategies and the use of specific mucosal immune response-inducing, non-invasive routes of administration, which must be considered early in the development process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
Lethal Infection of K18- hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus
McCray, P. B., Pewe, L., Wohlford-Lenane, C., Hickey, M., Manzel, L., Shi, L., Netland, J., Jia, H. P., Halabi, C., Sigmund, C. D., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02012-06 · Cited by 1,010
Freezing temperatures in the vaccine cold chain: A systematic literature review
Matthias, D. M., Robertson, J., Garrison, M. M., Newland, S., & Nelson, C. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.052 · Cited by 304
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
Clément, N., & Grieger, J. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.2 · Cited by 286
Research works printed but not linked: 68
- Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet [Internet]. 2020; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673620310229.
- Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet [Internet]. 2020;395(10238):1695–704 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673620310424.
- Murphy K, Casey W. Janeway’s immunobiology. 9th ed. New York: Garland Science; 2017. p. 729–41.
- Zepp F. Principles of vaccine design—lessons from nature. Vaccine [Internet]. 2010;28:C14–24 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X10010030. · DOI
- Hanley KA. The double-edged sword: how evolution can make or break a live-attenuated virus vaccine. Evol Educ Outreach [Internet]. 2011;4(4):635–43. https://doi.org/10.1007/s12052-011-0365-y (Available from:). · DOI
- Offit PA. The cutter incident, 50 years later. N Engl J Med [Internet]. 2005;352(14):1411–2. Available from:. https://doi.org/10.1056/NEJMp048180. · DOI
- Vartak A, Sucheck S. Recent advances in subunit vaccine carriers. Vaccines [Internet]. 2016;4(2):12 Available from: http://www.mdpi.com/2076-393X/4/2/12. · DOI · Paper page
- Li F, Li W, Farzan M, Harrison SC. Structural biology: structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864–8. · DOI · Paper page
- Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol [Internet]. 2015;13:123–9 Available from: https://linkinghub.elsevier.com/retrieve/pii/S187962571500098X. · DOI
- Marzi A, Gramberg T, Simmons G, Möller P, Rennekamp AJ, Krumbiegel M, et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol [Internet]. 2004;78(21):12090–5 Available from: https://jvi.asm.org/content/78/21/12090. · DOI · Paper page
- Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, et al. Immunization with modified Vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol [Internet]. 2004;78(22):12672–6 Available from: https://jvi.asm.org/content/78/22/12672. · DOI · Paper page
- Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. bioRxiv. 2020. · DOI
- Lapelosa M, Gallicchio E, Arnold GF, Arnold E, Levy RM. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes. J Mol Biol [Internet]. 2009;385(2):675–91 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022283608014022. · DOI
- Shamriz S, Ofoghi H. Design, structure prediction and molecular dynamics simulation of a fusion construct containing malaria pre-erythrocytic vaccine candidate, PfCelTOS, and human interleukin 2 as adjuvant. BMC Bioinformatics [Internet]. 2016;17(1):–71 Available from: http://www.biomedcentral.com/1471-2105/17/71. · doi:10.1186/s12859-016-0918-8
- Chaudhury S, Duncan EH, Atre T, Storme CK, Beck K, Kaba SA, et al. Identification of immune signatures of novel adjuvant formulations using machine learning. Sci Rep [Internet]. 2018;8(1):17508 Available from: http://www.nature.com/articles/s41598-018-35452-x. · DOI
- Chaudhury S, Duncan EH, Atre T, Dutta S, Spring MD, Leitner WW, et al. Combining immunoprofiling with machine learning to assess the effects of adjuvant formulation on human vaccine-induced immunity. Hum Vaccin Immunother [Internet]. 2020;16(2):400–11. Available from:. https://doi.org/10.1080/21645515.2019.1654807. · DOI
- Ong E, Wong MU, Huffman A, He Y. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. bioRxiv [Internet]. 2020 ;2020.03.20.000141. Available from: http://biorxiv.org/content/early/2020/03/21/2020.03.20.000141.abstract
- He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun [Internet]. 2004;324(2):773–81 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0006291X04021588. · DOI · Paper page
- Du L, Zhao G, He Y, Guo Y, Zheng B-J, Jiang S, et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine [Internet]. 2007;25(15):2832–8 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0264410X06011534. · DOI
- Fang M, Cheng H, Dai Z, Bu Z, Sigal LJ. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology [Internet]. 2006;345(1):231–43 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0042682205006306. · DOI
- Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and protective antibodies directed against Vaccinia virus envelope antigens. Virology [Internet]. 1999;254(1):71–80 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0042682298995162. · DOI · Paper page
- Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, et al. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS. J Immunol [Internet]. 2008;180(2):948–56. Available from:. https://doi.org/10.4049/jimmunol.180.2.948. · DOI
- Detmer A, Glenting J. Live bacterial vaccines—a review and identification of potential hazards. Microb Cell Fact. 2006;5(iii):1–12.
- Montel Mendoza G, Pasteris SE, Otero MC, Fatima Nader-Macías ME. Survival and beneficial properties of lactic acid bacteria from raniculture subjected to freeze-drying and storage. J Appl Microbiol. 2014;116(1):157–66. · doi:10.1111/jam.12359
- Thi EP, Mire CE, Lee ACH, Geisbert JB, Zhou JZ, Agans KN, et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature [Internet]. 2015;521(7552):362–5 Available from: http://www.nature.com/articles/nature14442. · DOI · Paper page
- Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012;9(11):1319–30. · DOI · Paper page
- Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained immunity-based vaccines: a new paradigm for the development of broad-Spectrum anti-infectious formulations. Front Immunol. 2018;9(December):2936. · DOI · Paper page
- Quintin J, Saeed S, Martens JHA, Giamarellos-Bourboulis EJ, Ifrim DC, Logie C, et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe [Internet]. 2012;12(2):223–32 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1931312812002326. · DOI · Paper page
- Angelidou A, Conti MG, Diray-Arce J, Benn CS, Shann F, Netea MG, et al. Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation. Vaccine [Internet]. 2020;38(9):2229–40. Available from:. https://doi.org/10.1016/j.vaccine.2019.11.060. · doi:10.1016/j.vaccine.2019.11.060
- Editor CBF, Walker JM. Vaccine adjuvants [Internet]. In: Fox CB, editor. Methods in Molecular Biology, vol. 1494). Available from:. New York: Springer New York; 2017. https://doi.org/10.1007/978-1-4939-6445-1. · doi:10.1007/978-1-4939-6445-1
- Kool M, Soullié T, van Nimwegen M, Willart MAM, Muskens F, Jung S, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med [Internet]. 2008;205(4):869–82. Available from:. https://doi.org/10.1084/jem.20071087. · DOI · Paper page
- Kool M, Petrilli V, De Smedt T, Rolaz A, Hammad H, van Nimwegen M, et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol [Internet]. 2008;181(6):3755–9. Available from:. https://doi.org/10.4049/jimmunol.181.6.3755. · DOI · Paper page
- Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LÅ. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun. 2001;69(2):1151–9. · DOI
- Khurana S, Coyle EM, Manischewitz J, King LR, Gao J, Germain RN, et al. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. NPJ vaccines [Internet]. 2018;3(March):40. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30302282%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6167326. · DOI
- Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol [Internet]. 2009;183(10):6186–97. Available from:. https://doi.org/10.4049/jimmunol.0901474. · DOI · Paper page
- Schell B, Braedel S, Probst J, Carralot JP, Wagner H, Schild H, et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol. 2004;34(2):537–47. · DOI
- Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology [Internet]. 2006;344(1):230–9 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0042682205005891. · DOI
- Faust N. Addressing the challenges of commercial-scale viral vector production. Cell Gene Ther Insights. 2018;4(2):31–6. · doi:10.18609/cgti.2018.004
- Vellinga J, Smith JP, Lipiec A, Majhen D, Lemckert A, van Ooij M, et al. Challenges in manufacturing adenoviral vectors for global vaccine product deployment. Hum Gene Ther. 2014;25(4):318–27. · doi:10.1089/hum.2014.007
- Terova O, Soltys S, Hermans P, De Rooij J, Detmers F. Overcoming downstream purification challenges for viral vector manufacturing: enabling advancement of gene therapies in the clinic. Cell Gene Ther Insights. 2018;4(2):101–11. · doi:10.18609/cgti.2018.017
- Merten O-W, Schweizer M, Chahal P, Kamen A. Manufacturing of viral vectors: part II. Downstream processing and safety aspects. Pharm Bioprocess. 2014. · DOI
- Bandeira V, Peixoto C, Rodrigues AF, Cruz PE, Alves PM, Coroadinha AS, et al. Downstream processing of lentiviral vectors: releasing bottlenecks. Hum Gene Ther Methods. 2012;23:255–63. · DOI
- Gramer MJ. Product quality considerations for mammalian cell culture process development and manufacturing. Adv Biochem Eng Biotechnol. 2014. · DOI
- ZOLGENSMA. Package insert. Bannockburn: AveXis, Inc.; 2019.
- Niu L, Panyam J. Freeze concentration-induced PLGA and polystyrene nanoparticle aggregation: Imaging and rational design of lyoprotection. J Control Release [Internet]. 2017;248:125–132. Available from: https://doi.org/10.1016/j.jconrel.2017.01.019 · DOI
- Pastorino B, Baronti C, Gould EA, Charrel RN, de Lamballerie X. Effect of Chemical Stabilizers on the Thermostability and Infectivity of a Representative Panel of Freeze Dried Viruses. Digard P, editor. PLoS One [Internet]. 2015;10(4):e0118963. Available from:. https://doi.org/10.1371/journal.pone.0118963. · DOI
- Zhang Y, Zhang J. Surface modification of monodisperse magnetite nanoparticles for improved intracellular uptake to breast cancer cells. J Colloid Interface Sci [Internet]. 2005;283(2):352–7 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0021979704009592. · DOI
- Acar HY c, Garaas RS, Syud F, Bonitatebus P, Kulkarni AM. Superparamagnetic nanoparticles stabilized by polymerized PEGylated coatings. J Magn Magn Mater [Internet]. 2005;293(1):1–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0304885305001009. · DOI
- Offit PA, Jew RK. Addressing parents’ concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics [Internet]. 2003;112(6):1394–7. Available from:. https://doi.org/10.1542/peds.112.6.1394. · DOI
- Tischer A, Lilie H, Rudolph R, Lange C. L-arginine hydrochloride increases the solubility of folded and unfolded recombinant plasminogen activator rPA. Protein Sci [Internet]. 2010;19(9):1783–95. Available from:. https://doi.org/10.1002/pro.465. · doi:10.1002/pro.465
- Baynes BM, Wang DIC, Trout BL. Role of arginine in the stabilization of proteins against aggregation. Biochem Int. 2005;44(12):4919–25. Available from:. https://doi.org/10.1021/bi047528r. · DOI · Paper page
- Das U, Hariprasad G, Ethayathulla AS, Manral P, Das TK, Pasha S, et al. Inhibition of protein aggregation: supramolecular assemblies of arginine hold the key. Rutherford S, editor. PLoS One [Internet]. 2007;2(11):e1176. Available from:. https://doi.org/10.1371/journal.pone.0001176. · doi:10.1371/journal.pone.0001176
- Morefield GL. A rational, systematic approach for the development of vaccine formulations. AAPS J. 2011;13(2):191–200. · DOI
- Engstrom JD, Lai ES, Ludher BS, Chen B, Milner TE, Williams RO, et al. Formation of stable submicron protein particles by thin film freezing. Pharm Res. 2008;25(6):1334–46. · DOI
- Li X, Thakkar SG, Ruwona TB, Williams RO, Cui Z. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution. J Control Release [Internet]. 2015;204:38–50. Available from:. https://doi.org/10.1016/j.jconrel.2015.02.035. · DOI
- Aso Y, Yoshioka S. Effect of freezing rate on physical stability of lyophilized cationic liposomes. Chem Pharm Bull (Tokyo) [Internet]. 2005;53(3):301–4 Available from: http://joi.jlc.jst.go.jp/JST.JSTAGE/cpb/53.301?from=CrossRef. · DOI
- Thakkar SG, Ruwona TB, Williams RO, Cui Z. The immunogenicity of thin-film freeze-dried, aluminum salt-adjuvanted vaccine when exposed to different temperatures. Hum Vaccines Immunother [Internet]. 2017;13(4):936–46. Available from:. https://doi.org/10.1080/21645515.2016.1259042. · DOI
- Xu H, Ruwona TB, Thakkar SG, Chen Y, Zeng M, Cui Z. Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses. Hum Vaccines Immunother. 2017;13(11):2688–94. · DOI
- Thakkar SG, Warnken ZN, Alzhrani RF, Valdes SA, Aldayel AM, Xu H, et al. Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine. J Control Release [Internet]. 2018;292:111–8. Available from:. https://doi.org/10.1016/j.jconrel.2018.10.020. · DOI
- Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol. 2009;183(11):6883–92. · DOI
- Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release [Internet]. 2010;147(3):342–9. Available from:. https://doi.org/10.1016/j.jconrel.2010.08.012. · DOI
- Tomar J, Tonnis WF, Patil HP, de boer AH, Hagedoorn P, Vanbever R, et al. Pulmonary immunization: deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination. Acta Pharm Sin B [Internet]. 2019;9(6):1231–40. Available from:. https://doi.org/10.1016/j.apsb.2019.05.003. · DOI
- Kulkarni PS, Raut SK, Dhere RM. A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac ® ) in India. Hum Vaccin Immunother [Internet]. 2013;9(1):122–4. Available from:. https://doi.org/10.4161/hv.22317. · doi:10.4161/hv.22317
- Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med [Internet]. 2004;350(9):896–903. Available from:. https://doi.org/10.1056/NEJMoa030595. · DOI · Paper page
- Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ [Internet]. 2013;346:f794. Available from:. https://doi.org/10.1136/bmj.f794. · DOI · Paper page
- Connell TD. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev Vaccines [Internet]. 2007;6(5):821–34. Available from:. https://doi.org/10.1586/14760584.6.5.821. · DOI
- Linehan JL, Dileepan T, Kashem SW, Kaplan DH, Cleary P, Jenkins MK. Generation of Th17 cells in response to intranasal infection requires TGF-β1 from dendritic cells and IL-6 from CD301b + dendritic cells. Proc Natl Acad Sci [Internet]. 2015;112(41):12782–7. Available from:. https://doi.org/10.1073/pnas.1513532112. · DOI
- Astudillo A, Leung SSY, Kutter E, Morales S, Chan H-K. Nebulization effects on structural stability of bacteriophage PEV 44. Eur J Pharm Biopharm [Internet]. 2018;125(December 2017):124–30 Available from: https://linkinghub.elsevier.com/retrieve/pii/S093964111731007X. · doi:10.1016/j.ejpb.2018.01.010
Cited by
COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates
Sallam, M. (2021) · Vaccines · doi:10.3390/vaccines9020160 · Cited by 2,128
Sallam, M., Dababseh, D., Eid, H., Al-Mahzoum, K., Al-Haidar, A., Taim, D., Yaseen, A., Ababneh, N. A., Bakri, F. G., & Mahafzah, A. (2021) · Vaccines · doi:10.3390/vaccines9010042 · Cited by 675
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination
Müller, L., Andrée, M., Moskorz, W., Drexler, I., Walotka, L., Grothmann, R., Ptok, J., Hillebrandt, J., Ritchie, A., Rabl, D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab381 · Cited by 511
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Uddin, M. N., & Roni, M. A. (2021) · Vaccines · doi:10.3390/vaccines9091033 · Cited by 371
Giordano, G., Colaneri, M., Di Filippo, A., Blanchini, F., Bolzern, P., De Nicolao, G., Sacchi, P., Colaneri, P., & Bruno, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01334-5 · Cited by 192
Metadata
- Authors
- Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O.
- Venue
- AAPS PharmSciTech
- Published
- 2020-08
- Volume
- 21
- Issue
- 6
- Pages
- 225-225
- ISSN
- 1530-9932 (ISSN-L)
- OpenAlex
- W3047135833
- Cited by
- 327
- References
- 14
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. https://app.cochat.ai/papers/10.1208/s12249-020-01744-7
- The paper
- Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. (2020). The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech. https://doi.org/10.1208/s12249-020-01744-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.